Seung-Hee Kwon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seung-Hee Kwon has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Gun-Woo Lee
Department of Orthopedic Surgery, Chonnam National University Hospital, Gwangju, Republic of Korea
1 shared publication - Gyuseok Lee
Department of Pharmacology and Dental Therapeutics, School of Dentistry, Chonnam National University, Gwangju, Republic of Korea
1 shared publication - Hae Jin Kee
Heart Research Center of Chonnam National University Hospital, Gwangju, Republic of Korea
1 shared publication - Hyo-Eun Kim
Department of Pharmacology and Dental Therapeutics, School of Dentistry, Chonnam National University, Gwangju, Republic of Korea
1 shared publication - Jang-Soo Chun
School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea
1 shared publication - Je-Hwang Ryu
Department of Pharmacology and Dental Therapeutics, School of Dentistry, Chonnam National University, Gwangju, Republic of Korea
1 shared publication
Latest Publications
- 1 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 394 (6819)
Hypertension fuels osteoarthritis through neuroendocrine signaling
Osteoarthritis (OA) is a degenerative joint disease, the progression of which is accelerated by systemic metabolic stress. Here, we identified a neuroendocrine pathway through which hypertension accelerates OA pathogenesis in joints predisposed by mechanical injury or aging. Nationwide cohort analyses and hypertensive mouse models demonstrated that elevated blood pressure exacerbates OA pathogenesis. OA-primed chondrocytes up-regulated arginine vasopressin (AVP) receptor 1A (AVPR1A), rendering them responsive to hypertension-associated circulating AVP. AVP-AVPR1A signaling enhanced catabolic signaling while suppressing anabolic regulators, thereby promoting cartilage catabolism. Genetic deletion or pharmacological inhibition of AVPR1A protected against hypertension-driven OA acceleration. Transcriptomic profiling and gene-silencing analyses identified NR4A3 as the principal downstream transcriptional mediator. Collectively, these findings establish the AVP-AVPR1A axis as a mechanistic link between systemic hypertensive stress and joint degeneration.
- 1 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 394 (6819)
Hypertension fuels osteoarthritis through neuroendocrine signaling
Osteoarthritis (OA) is a degenerative joint disease, the progression of which is accelerated by systemic metabolic stress. Here, we identified a neuroendocrine pathway through which hypertension accelerates OA pathogenesis in joints predisposed by mechanical injury or aging. Nationwide cohort analyses and hypertensive mouse models demonstrated that elevated blood pressure exacerbates OA pathogenesis. OA-primed chondrocytes up-regulated arginine vasopressin (AVP) receptor 1A (AVPR1A), rendering them responsive to hypertension-associated circulating AVP. AVP-AVPR1A signaling enhanced catabolic signaling while suppressing anabolic regulators, thereby promoting cartilage catabolism. Genetic deletion or pharmacological inhibition of AVPR1A protected against hypertension-driven OA acceleration. Transcriptomic profiling and gene-silencing analyses identified NR4A3 as the principal downstream transcriptional mediator. Collectively, these findings establish the AVP-AVPR1A axis as a mechanistic link between systemic hypertensive stress and joint degeneration.